FDA-approved blood test offers new hope for Alzheimer’s diagnosis

(Aging Untold) — The FDA’s first-ever approval of a blood test to help diagnose Alzheimer’s disease marks a significant step forward in treating a condition that affects about 7 million Americans, with that number expected to nearly double by 2060, according to the Alzheimer’s Association. The blood test, known as Lumipulse, was approved by the FDA in May 2025 as a “less invasive option” that “reduces reliance on PET scans and increases diagnosis accessibility.” Breakthrough in accessibility Rebecca Edelmayer, vice president of scientific engagement for the Alzheimer’s Association, said getting a diagnosis can be difficult and time-consuming. “One of the things that we continue to see is that for some patients it could take years,” Edelmayer said. “And we know that having an early and accurate diagnosis is so critical — especially when there’s treatments that have been approved today, to really help slow down the disease process.” Traditional diagnosis often involves referrals to speci